Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

10. November 2014 aktualisiert von: Pfizer

A Phase 2a, Randomized, Double-blind, Sponsor Unblinded, Placebo-controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Subjects With Active Ulcerative Colitis

This study represents the first investigation of anrukinzumab in patients with active ulcerative colitis (UC) and will evaluate proof of mechanism by changes in the mechanism based biomarker (YKL 40) and pharmacodynamic biomarkers (fecal calprotectin, lactoferrin and hs-CRP). It will provide further assessment of the safety, tolerability, and pharmacokinetics (PK) by administration of multiple intravenous (IV) doses of anrukinzumab.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

84

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Bulgarien
      • Ruse, Bulgarien, 7002
        • MBAL Ruse / MHAT Ruse, Terapevtichno, gastroenterologichno i hematologichno otdelenie
      • Sofia, Bulgarien, 1606
        • MBAL Voennomeditsinska Akademia / MMA HAT, Klinika po gastroenterologia i hepatologia
      • Sofia, Bulgarien, 1750
        • DKTs Sveta Anna, Gastroenterologichen cabinet
  • Deutschland
      • Berlin, Deutschland, 10117
        • Charite - Campus Berlin Mitte
      • Heidelberg, Deutschland, 69120
        • Universitaetsklinikum Heidelberg
      • Kiel, Deutschland, 24105
        • Universitaetsklinikum Schleswig-Holstein, Campus Kiel
      • Minden, Deutschland, 32423
        • Gastroenterologische Gemeinschaftspraxis Minden
  • Frankreich
      • Amiens Cedex 01, Frankreich, 80054
        • CHU Hopital Nord
      • Clichy, Frankreich, 92110
        • Hôpital Beaujon
      • Nantes CEDEX 1, Frankreich, 44093
        • CHU Hotel-Dieu
  • Kanada
    • Alberta
      • Calgary, Alberta, Kanada, T2N 4Z6
        • Heritage Medical Research Clinic - University Of Calgary
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z 1M9
        • Vancouver Coastal Health - Vancouver General Hospital
      • Vancouver, British Columbia, Kanada, V5Z 1M9
        • Vancouver General Hospital - The Gordon and Leslie Diamond Centre
    • Ontario
      • Kingston, Ontario, Kanada, K7L 5G2
        • The Religious Hospitallers of St. Joseph of the Hotel Dieu of Kingston
      • Toronto, Ontario, Kanada, M4N 3M5
        • Sunnybrook Health Sciences Centre
  • Niederlande
      • Amsterdam, Niederlande, 1081 HV
        • VU Medisch Centrum
      • Amsterdam, Niederlande, 1105 AZ
        • Academic Medical Center - University of Amsterdam, Dept. of Gastroenterology
      • Maastricht, Niederlande, 6229 HX
        • Academisch Ziekenhuis Maastricht
  • Polen
      • Warszawa, Polen, 02-507
        • Centralny Szpital Kliniczny MSWiA, Klinika Chorob Wewnetrznych i Gastroenterologii
  • Rumänien
      • Bucuresti, Rumänien, 010816
        • Sectia Clinica Medicina Interna II
  • Spanien
      • Barcelona, Spanien, 08036
        • Hospital Clinic i Provincial de Barcelona
      • Madrid, Spanien, 28007
        • Hospital General Universitario Gregorio Marañón
  • Ungarn
      • Budapest, Ungarn, 1136
        • Pannonia Maganorvosi Centrum Kft.
      • Budapest, Ungarn, 1125
        • Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszati-Gasztroenterologiai Osztaly
      • Szekszard, Ungarn, 7100
        • Clinfan Kft.
  • Vereinigte Staaten
    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35249
        • UAB Hospital Department of Pharmacy
      • Birmingham, Alabama, Vereinigte Staaten, 35233
        • UAB Hospital
      • Birmingham, Alabama, Vereinigte Staaten, 35233
        • The Kirkland Clinic
      • Birmingham, Alabama, Vereinigte Staaten, 35294
        • Administrative Offices
      • Birmingham, Alabama, Vereinigte Staaten, 35294
        • UAB ACIP
    • Arizona
      • Phoenix, Arizona, Vereinigte Staaten, 85013
        • Dedicated Phase I, Inc.
      • Phoenix, Arizona, Vereinigte Staaten, 85006
        • Arizona Surgical Center
    • California
      • Anaheim, California, Vereinigte Staaten, 92801
        • Anaheim Clinical Trials, LLC
      • Anaheim, California, Vereinigte Staaten, 92801
        • AGMG Endoscopy Center
      • Santa Ana, California, Vereinigte Staaten, 92705
        • West Coast Radiology Center
    • Connecticut
      • Hamden, Connecticut, Vereinigte Staaten, 06518
        • Medical Research Center of Connecticut, LLC
      • Hamden, Connecticut, Vereinigte Staaten, 06518
        • Gastroenterology Center of Connecticut, PC
      • Hamden, Connecticut, Vereinigte Staaten, 06518
        • Endoscopy Center of Connecticut, LLC
    • Florida
      • Sanford, Florida, Vereinigte Staaten, 32771
        • International Clinical Research - US, LLC
    • Georgia
      • Marietta, Georgia, Vereinigte Staaten, 30060
        • Gastrointestinal Specialists of Georgia, PC
      • Marietta, Georgia, Vereinigte Staaten, 30067
        • GI Diagnostics
    • Mississippi
      • Jackson, Mississippi, Vereinigte Staaten, 39216
        • St. Dominic Hospital
      • Jackson, Mississippi, Vereinigte Staaten, 39202
        • Gastrointestinal Associates, PA
      • Jackson, Mississippi, Vereinigte Staaten, 39202
        • Gastrointestional Associates, PA
      • Tupelo, Mississippi, Vereinigte Staaten, 38801
        • North Mississippi Medical Center
      • Tupelo, Mississippi, Vereinigte Staaten, 38801
        • Digestive Health Specialists, PA
    • New York
      • Poughkeepsie, New York, Vereinigte Staaten, 12601
        • Premier Medical Group of the Hudson Valley
    • North Carolina
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27103
        • PMG Research of Winston-Salem
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27103
        • Piedmont Gastroenterology Specialists
    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 44106
        • University Hospitals Case Medical Center - Division of Gastroenterology and Liver Disease
    • Oklahoma
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
        • Oklahoma Foundation for Digestive Research
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
        • OU Physicians Building
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73103
        • Wheeler and Stuckey, Inc.
    • Tennessee
      • Germantown, Tennessee, Vereinigte Staaten, 38138
        • Memphis Gastroenterology Group, PC
      • Memphis, Tennessee, Vereinigte Staaten, 38120
        • The West Clinic
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • Centennial Medical Center Physicians Park
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • Centennial Medical Center Tower Medical Imaging
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • Columbia Medical Group - The First Clinic Inc.
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • Radiology Alliance
    • Texas
      • Austin, Texas, Vereinigte Staaten, 78705
        • Professional Quality Research, Inc.
      • Austin, Texas, Vereinigte Staaten, 78757
        • Austin Endoscopy Center
      • Austin, Texas, Vereinigte Staaten, 78757
        • Austin Gastroenterology, PA
      • Houston, Texas, Vereinigte Staaten, 77081
        • Texas Center for Drug Development, Inc.
      • Round Rocks, Texas, Vereinigte Staaten, 78681
        • Austin Gastroenterology, PA
      • San Antonio, Texas, Vereinigte Staaten, 78229
        • Cardiology Clinic of San Antonio
      • San Antonio, Texas, Vereinigte Staaten, 78229
        • Gastroenterology Research of San Antonio
      • San Antonio, Texas, Vereinigte Staaten, 78229
        • San Antonio Endoscopy Center
    • Utah
      • Murray, Utah, Vereinigte Staaten, 84123
        • CNS Pharmacy
      • Salt Lake City, Utah, Vereinigte Staaten, 84132
        • University of Utah Hospital
      • Salt Lake City, Utah, Vereinigte Staaten, 84102
        • Alpine Medical Group
      • Salt Lake City, Utah, Vereinigte Staaten, 84107
        • Wasatch Clinical Research
      • Salt Lake City, Utah, Vereinigte Staaten, 84124
        • Wasatch Endoscopy Center
      • Salt Lake City, Utah, Vereinigte Staaten, 84084
        • RGL Medical Services
  • Österreich
      • Linz, Österreich, 4020
        • Krankenhaus der Elisabethinen Linz GmbH
      • St. Poelten, Österreich, 3100
        • Landesklinikum St. Poelten
      • Wien, Österreich, 1090
        • AKH Wien Universitaetsklinik fuer Innere Medizin III

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Male or Female, Age >=18 and <=65 years
  • Active ulcerative colitis (UC) beyond the rectum based upon Mayo Score
  • women of childbearing potential with highly effective method of contraception

Exclusion Criteria:

  • Indeterminate disease status, Crohn's disease, ischemic colitis, positive HIV, positive or history of tuberculosis infection, active enteric infections, transplant organ recipient, concomitant steroids, immunosuppressives or anti-TNFs.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Arm 1
200 mg PF-05230917, Anrukinzumab active dose level
Biologisch: Anrukinzumab
200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
Andere Namen:
  • PF-05230917
Biologisch: Anrukinzumab
200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
Andere Namen:
  • PF-05230917
Biologisch: Anrukinzumab
200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
Andere Namen:
  • PF-05230917
Experimental: Arm 2
400 mg PF-05230917, Anrukinzumab active dose level
Biologisch: Anrukinzumab
200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
Andere Namen:
  • PF-05230917
Biologisch: Anrukinzumab
200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
Andere Namen:
  • PF-05230917
Biologisch: Anrukinzumab
200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
Andere Namen:
  • PF-05230917
Experimental: Arm 3
600 mg PF-05230917, Anrukinzumab active dose level
Biologisch: Anrukinzumab
200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
Andere Namen:
  • PF-05230917
Biologisch: Anrukinzumab
200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
Andere Namen:
  • PF-05230917
Biologisch: Anrukinzumab
200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
Andere Namen:
  • PF-05230917
Placebo-Komparator: Arm 4
Matching placebo - administered at matching dose level 200 mg, 400 mg or 600 mg.
Sonstiges: placebo
200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Fold Change From Baseline in Fecal Calprotectin at Week 14
Zeitfenster: Baseline, Week 14
The fold change from baseline in fecal calprotectin at Week 14, is the ratio of the measurement of fecal calprotectin at Week 14 to baseline measurement; this was calculated as the change from baseline in natural log transformed fecal calprotectin at Week 14.
Baseline, Week 14

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Maximum Observed Plasma Concentration (Cmax) for Anrukinzumab
Zeitfenster: Pre-dose to end of the dosing interval after Day 1, Week 12
Maximum concentration observed during the dosing interval (2 weeks for day 1, 4 weeks for week 12).
Pre-dose to end of the dosing interval after Day 1, Week 12
Minimum Observed Plasma Trough Concentration (Cmin) for Anrukinzumab
Zeitfenster: Pre-dose to end of the dosing interval after Day 1, Week 12
Lowest concentration observed during the dosing interval (2 weeks for day 1, 4 weeks for week 12).
Pre-dose to end of the dosing interval after Day 1, Week 12
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for Anrukinzumab
Zeitfenster: Pre-dose, within 1 hour post-end of infusion on Day 1; Day 2, 4, 7, pre-dose on Week 2
Area under the plasma concentration curve from time zero to end of dosing interval (2 weeks) was reported.
Pre-dose, within 1 hour post-end of infusion on Day 1; Day 2, 4, 7, pre-dose on Week 2
Plasma Decay Half-Life (t1/2) for Anrukinzumab
Zeitfenster: Within 1 hour post-end of infusion on Week 12; Week 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Within 1 hour post-end of infusion on Week 12; Week 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Systemic Clearance (CL) for Anrukinzumab
Zeitfenster: Pre-dose, within 1 hour post-end of infusion on Week 12; Week 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
CL is a quantitative measure of the rate at which a drug substance is removed from the body.
Pre-dose, within 1 hour post-end of infusion on Week 12; Week 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Volume of Distribution (Vz) for Anrukinzumab
Zeitfenster: Pre-dose, within 1 hour post-end of infusion on Week 12; Week 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Pre-dose, within 1 hour post-end of infusion on Week 12; Week 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Fold Change From Baseline in Fecal Calprotectin at Week 2, 4, 8 and 12
Zeitfenster: Baseline, Week 2, 4, 8, 12
The fold change from baseline in fecal calprotectin at post-baseline visit, is the ratio of the measurement of fecal calprotectin at post-baseline visit to baseline measurement; this was calculated as the change from baseline in natural log transformed fecal calprotectin at post-baseline visit.
Baseline, Week 2, 4, 8, 12
Total Interleukin-13 (IL-13) Level
Zeitfenster: Baseline, Day 2, 4, 7, Week 2, 4, 8, 12, 14, 16, 20, 24, 28, 32
Baseline, Day 2, 4, 7, Week 2, 4, 8, 12, 14, 16, 20, 24, 28, 32
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: Baseline up to Week 32
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 32 that were absent before treatment or that worsened relative to pretreatment state. All causality AEs included SAEs as well as non-serious AEs, without regard to relationship to the study drug, which occurred during the trial.
Baseline up to Week 32
Number of Participants Who Discontinued From the Study Due to Adverse Events
Zeitfenster: Baseline up to Week 32
Baseline up to Week 32
Number of Participants With Anti-drug Antibody (ADA) and Neutralizing Antibody
Zeitfenster: Day 1, Week 4, 8, 12, 14, 16, 20, 24, 28, 32
Neutralizing antibody was not analyzed as no participant had positive ADA samples.
Day 1, Week 4, 8, 12, 14, 16, 20, 24, 28, 32
Number of Participants With Change From Baseline in Endoscopic Subscore at Week 14
Zeitfenster: Baseline, Week 14
Mayo score is used to measure the disease activity of ulcerative colitis. Endoscopy or flexible sigmoidoscopy is a sub score of Mayo score. The score for endoscopic subscore ranges from 0 to 3, where higher score indicates more severe disease activity. Participant's score for endoscopy or flexible sigmoidoscopy at Week 14 was specified as improved (decrease), no change and worsened (increase) compared to their baseline score.
Baseline, Week 14

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Clinical Response Rate at Week 14
Zeitfenster: Week 14
Clinical response rate is defined as percentage of participants with at least 3 point decrease from baseline in total Mayo score with at least 30% change along with 1 point decrease from baseline or absolute score of 0 or 1 in rectal bleeding. The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Mayo score ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, findings on flexible sigmoidoscopy [endoscopy] and physician's global assessment), each subscore is graded from 0 to 3 with the higher score indicating more severe disease activity.
Week 14
Clinical Remission Rate at Week 14
Zeitfenster: Week 14
Clinical remission rate is defined as percentage of participants with a total Mayo score less than or equal to 2, with no individual subscore greater than 1 at post baseline visit. The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Mayo score ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, findings on flexible sigmoidoscopy and physician's global assessment), each subscore is graded from 0 to 3 with the higher score indicating more severe disease activity.
Week 14
Change From Baseline in Total Mayo Score at Week 14
Zeitfenster: Baseline, Week 14
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Mayo score ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, findings on flexible sigmoidoscopy [endoscopy] and physician's global assessment), each subscore is graded from 0 to 3 with the higher score indicating more severe disease activity.
Baseline, Week 14
Number of Participants With Change From Baseline in Stool Frequency at Week 14
Zeitfenster: Baseline, Week 14
Stool frequency is a sub score of Mayo score used to measure the disease activity of ulcerative colitis. The score for stool frequency ranges from 0 to 3, where higher score indicates more severe disease activity. Participant's score for stool frequency at Week 14 was specified as improved (decrease), no change and worsened (increase) compared to their baseline score.
Baseline, Week 14
Number of Participants With Change From Baseline in Rectal Bleeding at Week 14
Zeitfenster: Baseline, Week 14
Mayo score is used to measure the disease activity of ulcerative colitis. Rectal bleeding is a sub score of Mayo score. The score for rectal bleeding ranges from 0 to 3, where higher score indicates more severe disease activity. Participant's score for rectal bleeding at Week 14 was specified as improved (decrease), no change and worsened (increase) compared to their baseline score.
Baseline, Week 14

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Pfizer

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. März 2011

Primärer Abschluss (Tatsächlich)

1. April 2013

Studienabschluss (Tatsächlich)

1. April 2013

Studienanmeldedaten

Zuerst eingereicht

25. Januar 2011

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

25. Januar 2011

Zuerst gepostet (Schätzen)

26. Januar 2011

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

18. November 2014

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2014

Zuletzt verifiziert

1. November 2014

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • B2421003
  • IMA-638 Anti-IL13 mAb
  • 2010-023762-49 (EudraCT-Nummer)

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Kolitis, Geschwür

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in China

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren